Effect of incentive spirometry on pulmonary function test in post COVID-19 pneumonia patients

Loganathan D., Malavika D., D. Anandhi, Shirly M., Pugazhendhi S., N. Nalini Jayanthi


Loganathan D., Malavika D., D. Anandhi, Shirly M., Pugazhendhi S., N. Nalini JayanthiLoganathan D., Malavika D., D. Anandhi, Shirly M., Pugazhendhi S., N. Nalini Jayanthi – Effect of incentive spirometry on pulmonary function test in post COVID-19 pneumonia patients. Fizjoterapia Polska 2022; 22(5); 122-128

DOI: https://doi.org/10.56984/8ZG20AZsV

Abstract

Background. COVID-19 caused by SARS-CoV-2 virus was assigned as a pandemic by WHO. Fever, breathlessness, cough and expectoration indicates lung involvement in the form of pneumonia and its most common complications are pulmonary fibrosis, chronic respiratory failure and reduced quality of life. Incentive spirometry is the relevant therapy to enhance the normal lung function and improve quality of life. Aim. To find the effect of incentive spirometry on pulmonary function test in post COVID-19 pneumonia patients. Methodology. An experimental study with simple random sampling (lottery method) of 24 patients in age group (18-68 years). The participants were randomly divided into 2 groups. Group A received pharmacotherapy and incentive spirometry and Group B received only pharmacotherapy. Computerized spirometry and Diffusion lung capacity for carbon monoxide (DLCO) was used as diagnostic tool to measure pre & post test values for both groups. Intervention was given for 4 weeks and after 4 weeks, to analyze the spirometry values post-test was taken for both groups. Outcome measures. Forced expiratory volume in the first second (FEV1), Forced vital capacity (FVC), FEV1/FVC &DLCO. Results. Statistical analysis shows significant improvement (p < 0.05) between pretest and post test values on Pulmonary Function Tests (PFT) in both Group A&B whereas there was increase in the improvement in intervention group than control group. Conclusion. Incentive spirometry improved the lung volume and capacities on PFT in post COVID-19 pneumonia patients and also these patients have mainly restrictive lung pattern by the use of DLCO.

Keywords:
FEV1, FVC, FEV1/FVC, DLCO, post COVID-19 pneumonia patients, incentive spirometry

Pobierz/Download/下載/Cкачиваете Atsisiųskite straipsnį anglų kalba nemokamai

Evaluation of lung parenchyma before and after new oral antiviral treatment in hepatitis C patients

Mohammed A. El Nadi, Mohamed W. Zakaria, Hamed A. Abd Allah, Aly M. Ghorab, Marwa M. Shaaban


Mohammed A. El Nadi, Mohamed W. Zakaria, Hamed A. Abd Allah, Aly M. Ghorab, Marwa M. Shaaban – Evaluation of lung parenchyma before and after new oral antiviral treatment in hepatitis C patients. Fizjoterapia Polska 2022; 22(3); 88-93

Abstract
Background. Hepatitis C infection is a major reason for long-standing liver disorder with direct-acting antivirals were allowed for its treatment. Few studies aimed to assess pulmonary complications of direct acting antiviral. Purpose. This trial was conducted to assess the lung parenchymal affection in hepatitis C patients before and after three months treatment with oral (Direct) antiviral drugs (Sofospovir, Daclatasvir and Ribavirin). Methods. the study was conducted on 30 outpatient patients, Kasr El-Aini & Nasser Institute Hospital, Cairo, from April 2016 to December 2017. Patients were randomly allocated into two equal groups using computerized randomization software: Group A (study group): 15 patients that received oral antiviral drugs (Sofospuvir, Daclatasvir and Ribavirin) plus multivitamins for 3 months and Group B (control group): 15 patients received multivitamins drugs only for 3 months. Serology for HCV, HRCT were measured to ensure inclusion of the patient. Pulmonary function testing, diffusing capacity (DLCO) and carbon monoxide and Viremia testing were conducted to show effect of treatment. Results. There was statistically significant increase in the FEV1, FVC, DLCO SB, FEV1/FVC, and DLCO/VA after 3 months treatment course in study group. While control group showed significant increase in FEV1/FVC and significant worse in DLCO/VA after 3 months. As regard comparison of pulmonary function variables as well as % of its changes between two groups, study group showed significant increase in DLCO/VA (post) after 3 months treatment course. Conclusion. Oral Antiviral treatment was associated with improvement in pulmonary function. However, larger multicenter reports are needed for more evaluation.

Key words:
Hepatitis C, Direct-acting antiviral, DLCO

Pobierz/Download/下載/Cкачиваете Atsisiųskite straipsnį anglų kalba nemokamai